TGR-1202 (Umbralisib) in Treatment Na√Øve Patients With Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to see how safe and effective the investigational drug umbralisib (TGR-1202) is in individuals with Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
DRUG: Umbralisib
Overall Response Rate (Complete Response and Partial Response), Overall Response Rate (ORR) of Umbralisib Treatment will be determined according to the criteria of the International Workshop on Chronic Lymphocytic Leukemia. ORR is defined as the percent of participants who achieve Complete Response (CR) or Partial Response (PR). Due to early study termination, result data is provided as best response at End of Treatment/Study Termination., Up to 24 months
Progression Free Survival (PFS), Progression Free Survival (PFS) is defined as the interval from registration to the earlier of the first documentation of definitive disease progression or death from any cause., Up to 24 months|Number of Participants With Serious Adverse Events, Number of participants with adverse events after receiving one dose of Umbralisib.., Up to 15 months
The purpose of this study is to see how safe and effective the investigational drug umbralisib (TGR-1202) is in individuals with Chronic Lymphocytic Leukemia (CLL)